NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 971.6 DKK | -0.18% |
|
+4.73% | +39.12% |
| Jun. 06 | Novo Nordisk braces for Ozempic rivals in China | RE |
| Jun. 06 | European equities gain on tech boost in run-up to ECB | RE |
| Sales 2024 * | 291B 42.46B | Sales 2025 * | 351B 51.25B | Capitalization | 4,317B 631B |
|---|---|---|---|---|---|
| Net income 2024 * | 105B 15.27B | Net income 2025 * | 127B 18.61B | EV / Sales 2024 * | 14.9 x |
| Net Debt 2024 * | 17.41B 2.54B | Net cash position 2025 * | 8.9B 1.3B | EV / Sales 2025 * | 12.3 x |
| P/E ratio 2024 * |
41.7
x | P/E ratio 2025 * |
34.1
x | Employees | 66,015 |
| Yield 2024 * |
1.23% | Yield 2025 * |
1.48% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +3.96% | ||
| 1 week | +6.15% | ||
| Current month | +4.96% | ||
| 1 month | +14.32% | ||
| 3 months | +14.65% | ||
| 6 months | +43.45% | ||
| Current year | +39.42% |
1 week
913.40
974.50
1 month
881.60974.50
Current year
688.80974.50
1 year
504.40974.50
3 years
246.63974.50
5 years
156.00974.50
10 years
109.10974.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.75% | ||
| 10.45% | 5 M€ | +17.05% | ||
| 5.40% | 17 M€ | +8.31% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 971 | -0.24% | 341 407 |
| 24-06-06 | 973.3 | +3.96% | 3,883,931 |
| 24-06-04 | 936.2 | +1.33% | 2,134,460 |
| 24-06-03 | 923.9 | -0.37% | 2,360,259 |
| 24-05-31 | 927.3 | +1.13% | 5,539,486 |
Delayed Quote Nasdaq Copenhagen, June 06, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
920
DKK
Spread / Average Target
-5.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.42% | 630B | |
| +43.64% | 754B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B | |
| +1.39% | 124B |
- Stock Market
- Equities
- NOVO B Stock
